Industrial Consultancy & Sponsored Research (IC&SR) , IIT Madras
Technology Category/ Market
Technology: Purine-Quinolone Hybrids for Targeting Kinases; Industry: Manufacturing /Chemical, Pharmaceutical, Applications: Food & Pharma, Anti cancer drug development.
Market: The global Quinolones market size is projected $69.4B at a CAGR of 4.5% during 2023-2030.
Image Gallery
Problem Statement
- In the present era, abnormalities in kinase function are linked with many diseases such as cancer, inflammation, bipolar disorders, neurodegenerative disorders, & cardiovascular disorders.
- This makes kinases, as one of the most important drug targets against said disease. Further, a few prior arts have discussed & found that only antibody-based approaches have reached the level of clinical development & no small-molecule-based drug that acts by targeting IL17 release is available. Hence, there is a need to mitigate above challenges.
Technology
- Present invention describes a novel purine-quinolone compounds that have the ability to bind both the adenine binding pocket and phosphate binding region together and at the same time suppress the secretion of IL17.
- Further present invention describes purine-quinolone hybrids with potential ability to target kinases which are well-recognized therapeutic targets against cancer and other proliferative diseases.
- wherein R= hydrogen, alkyl, aryl, arylalkyl, heteroaryl, amino acids or peptides introduced through amide bonds;
- R’= hydrogen, halogen, NO2, NH2, NHR””, NR”” where R”” = alkyl, aryl, arylalkyl, heteroaryl, amino acids or peptides introduced through amide bonds;
- R’’= hydrogen, purines, other aromatic and heterocyclic systems;
- R’’’= hydrogen, alkyl, aryl, arylalkyl groups.
Key Features/ Value Proposition
- The quinolone derivatives of said present invention are presented herewith:
- purine moiety on aryl ring,
- carbonyl group at C4, and
- other substituents.
- Said compound is effective against diseases arising from irregularities associated with kinase function and/or IL17 signaling.
Questions about this Technology?
Contact for Licensing
sm-marketing@imail.iitm.ac.in
ipoffice2@iitm.ac.in
Research Lab
Prof. Muraleedharan K M
Department of Chemistry
Intellectual Property
IITM IDF Ref:1255
Patent No. 355534
Technology Readiness Level
TRL – 3
Proof of Concept ready & validated